Commentary on Long-term Effectiveness of Adjuvant Treatment in Parkinson Disease-Reply
JAMA Neurol
.
2022 Jul 1;79(7):726-727.
doi: 10.1001/jamaneurol.2022.1604.
Authors
Richard Gray
1
,
Crispin Jenkinson
1
,
Carl E Clarke
2
3
Affiliations
1
Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
2
Birmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom.
3
Department of Neurology, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom.
PMID:
35759259
DOI:
10.1001/jamaneurol.2022.1604
No abstract available
Publication types
Comment
MeSH terms
Chemotherapy, Adjuvant
Humans
Parkinson Disease* / drug therapy